CMV Infection, CMV Viremia, Cytomegalovirus Infections, Opportunistic Infections
Conditions
Keywords
Immunocompromised, Allogeneic Stem Cell Transplantation, Hematopoietic stem cell transplantation (HSCT), T-cell
Brief summary
The present trial will consist of the treatment of 20 pediatric and adult Hematopoietic Stem Cell Transplantation (HSCT) recipients or immunocompromised participants diagnosed with opportunistic Cytomegalovirus (CMV) infections with virus-specific, antigen-selected T-cells. CMV-specific T-cells will be isolated from donor leukapheresis products using the CliniMACS® Prodigy. Prior studies on transfer of CMV specific T-cells have been shown to be safe and efficacious in the treatment of CMV infections. The main trial objective is to evaluate the feasibility and safety of CMV-specific T-cell transfer in adult and pediatric participants suffering from CMV infections or reactivation following HSCT or due to other immunocompromised states (e.g.; primary immunodeficiency, cytotoxic therapy). Participants will be followed for one year.
Interventions
BIOLOGICALCMV-specific T-cells
Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMVspecific CD4+ and CD8+ T-cells
Sponsors
University of Wisconsin, Madison
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
single-center, open-label, single-arm, pilot study
Eligibility
Sex/Gender
ALL
Age
1 Months to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult or pediatric patient suffering from CMV reactivation/infections following HSCT or due to other immunocompromised states (e.g.; primary immunodeficiency, cytotoxic therapy). * CMV reactivation/viremia defined as positive (\>500 copies/ml) CMV qPCR and/or * Presence of symptoms secondary to CMV infection or evidence of invasive CMV infection (e.g. pneumonitis, colitis) AND * Patients must have ONE OF THE FOLLOWING CRITERIA: * Absence of an improvement of viral load after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir or foscarnet (decrease by at least 1 log, i.e. 10-fold), or * New, persistent and/or worsening CMV-related symptoms, signs and/or markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet, or * Have contraindications or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir or foscarnet, or * Known resistance to ganciclovir and/or foscarnet based on molecular testing. 2. Recipients of an allogeneic HSCT must be 28 days after stem cell infusion at the time of T-cell transfer. 3. Written informed consent given by patient or legal representative. 4. Minimum patient age 1 month. 5. Minimum weight 7 lbs. 6. Female patients of childbearing age with negative pregnancy tests. 7. Patient Karnofsky/Lansky Performance Status \>30%. 8. Donor eligible based on FACT infectious screening requirements.
Exclusion criteria
1. Patient with acute GVHD \> grade 2 or active moderate or severe chronic GVHD at time of T-cell transfer 2. Patient receiving steroids (\>1.0 mg/kg body weight (BW) prednisone equivalent) at the time of T-cell transfer 3. Patient received allogeneic HSCT less than 28 days prior to T-cell transfer 4. Patient treated with donor lymphocyte infusion (DLI) within 28 days prior to T-cell transfer 5. Patient treated with Thymoglobulin (ATG), Alemtuzumab or T-cell immunosuppressive monoclonal antibodies within 28 days. 6. Patient with organ dysfunction or failure as determined by Karnofsky (patients \>16 years) or Lansky (patients ≤16 years) score ≤30% (Appendix 5) 7. Patients with CMV retinitis 8. Concomitant enrollment in another clinical trial with endpoints interfering with this study 9. Any medical condition which could compromise participation in the study according to the investigator's assessment 10. Known HIV infection 11. Female patient who is pregnant or breast-feeding, or adult of reproductive potential not willing to use an effective method of birth control during study treatment. Note: Women of childbearing potential must have a negative serum pregnancy test at study entry. 12. Patients unwilling or unable to comply with the protocol or unable to give informed consent. Donor Eligibility: The original donor will be the first choice as source of T cells. If the original donor is not available for donation (such as NMDP donor, cord blood unit, or related donor not available) of peripheral mononuclear cells or does not meet all donor eligibility criteria (including donor selection criteria based on University of Wisconsin - Madison Standard Operating Procedures for the selection of allogeneic donors), alternative related donors will be selected, with preference for those who have full HLA matching in 6/6 loci over those with partial HLA matching (≥ 3/6 HLA loci). 1. All donors must be ≥ 18 years old, available, CMV IgG positive, eligible and capable of undergoing a single standard 2 blood volume leukapheresis. If original HSCT donor is not available, CMV IgG negative or ineligible, a CMV IgG positive fully matched or haploidentical family donor will be used. 2. Related donors must be at least partially HLA compatible, matching with recipient in at least 3/6 HLA loci (HLA-A, HLA-B and HLA-DRB1 will be considered for this). 3. Donors must be CMV IgG seropositive. 4. Donors must show CMV T-cell activation after incubation with MACS GMP PepTivator Peptide Pools of CMV pp65 before undergoing leukapheresis. 5. Donor must meet the criteria for donor selection defined in the Standard Operating Procedures of the University of Wisconsin Hospitals and Clinics Stem Cell Transplant Program and in FACT standards.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety: Time to Occurrence of GVHD | up to 12 weeks from CMV-VST infusion | Time to occurrence of acute GVHD of any grade or to occurrence of chronic GVHD will be evaluated using the Kaplan-Meier method to assess incidence and severity of acute or chronic GVHD from day of T-cell transfer. The first day of GVHD onset at a certain grade will be used to calculate a cumulative incidence curve for that GVHD grade, acute or chronic. Overall cumulative incidence curves will be computed along with the 95% confidence intervals until Week 12 after T-cell transfer with death considered as a competing risk. |
| Feasibility: Number of Days from Participant Enrollment to Administration of CMV-VST | up to 21 days from enrollment | The feasibility of this intervention will in part be accomplished by measuring the amount of time from participant enrollment to administration of Cytomegalovirus-Viral Specific T-Cells (CMV-VST). |
| Feasibility: Successful production of CMV-VST from donors | up to 21 weeks from enrollment | The feasibility of this intervention will be assessed by quantifying the number of successful productions of Cytomegalovirus-Viral Specific T-Cells (CMV-VST) on an intent to treat basis. |
| Safety: Number of Subjects who experience infusion-related adverse events following CMV-VST infusion | up to 4 hours after CMV-VST infusion | Incidence assessed by monitoring vital signs and specific adverse events |
| Safety: Number of Subjects who experience newly occurring acute GVHD grade 1 | up to 12 weeks from CMV-VST infusion | Incidence of subjects who experience newly occurring acute GVHD grade 1 |
| Safety: Number of subjects experiencing newly occurring acute GVHD grade ≥ 2 or experience aggravation of pre-existing acute GVHD | up to 12 weeks from CMV-VST infusion | Incidence of newly occurring acute GVHD grade ≥ 2 or increase in grade of pre-existing acute GVHD |
| Safety: Number of subjects experiencing chronic GVHD | up to 12 weeks from CMV-VST infusion | Incidence of chronic GVHD |
| The number of severe infusion-related adverse events or severe non-hematological adverse events | up to 28 days from CMV-VST infusion | Incidence of infusion-related adverse events ≥ grade 3 and non-hematological adverse events ≥ grade 4 after CMV-VST, which are not due to pre-existing infection or original malignancy or pre-existing condition |
| Feasibility: Number of Participants Who Drop-Out Before T-Cell Transfer | up to 21 days from enrollement | The feasibility of this intervention will in part be accomplished by measuring the number of dropped out participants before T-Cell Transfer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy: Time to ≥1 log change in viral load | up to 12 weeks from CMV-VST infusion | Evaluation of efficacy will in part be measured by time to ≥1 log change in viral load in days. |
| Efficacy: Number of Participants with CMV Clearance | up to 12 weeks from CMV-VST infusion | Evaluation of efficacy will in part be measured by the number of patients with CMV clearance, defined as negative Polymerase Chain Reaction (PCR) from Day 7 to Week 12 after T-cell transfer. |
| Efficacy: Time to CMV Clearance | up to 12 weeks from CMV-VST infusion | Evaluation of efficacy will in part be measured by the time to CMV clearance (defined as negative PCR) from Day 0 to first day of two subsequent negative CMV PCR studies. |
| Efficacy: Number of Participants with Reduction or Clearance of Clinical Symptoms | up to 12 weeks from CMV-VST infusion | Evaluation of efficacy will in part be measured by the number of participants with reduction or clearance of clinical symptoms of underlying CMV infection from Day 7 to Week 12 after T-cell transfer as compared to Day 0. |
| Efficacy: Number of CMV Reactivations Following Initial Viral Clearance | up to 52 weeks from CMV-VST infusion | Evaluation of efficacy will in part be measured by the number of CMV reactivations following initial viral clearance until Week 52. |
| Efficacy: Overall Survival | up to 52 weeks | Evaluation of efficacy will in part be measured by the overall survival. Overall survival rate (OS): time from T-cell transfer (Day 0) to death or last follow-up throughout the study from Day 1 to Week 52. |
| Efficacy: Percentage of Participants with a ≥1 log decrease in CMV viral load | up to 12 weeks from CMV-VST infusion | Evaluation of efficacy will in part be measured by percentage of participants with a ≥1 log decrease in CMV viral load at Week 12. |
Countries
United States
Outcome results
None listed